Turtle Cameron — SEC insider filings
SEC reporting owner CIK 1758363. 31 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers all 31 filings on record, filed 2020-09-02 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 61 legs across 23 filings — 313,204 shares, $18,825,797 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 47.
- Largest priced transaction: sale of 11,445 shares @ $112.19 ($1,284,018) in Eidos Therapeutics, Inc., filed 2020-12-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | Chief Executive Officer, Director | 16 | — | 40 legs · 210,000 sh · $11,374,650 | 6 |
| Eidos Therapeutics, Inc. (EIDX) | Chief Business Officer | 5 | — | 11 legs · 54,704 sh · $4,939,477 | 14 |
| BridgeBio Pharma, Inc. (BBIO) | See Remarks | 8 | — | 10 legs · 48,500 sh · $2,511,670 | 25 |
| Damora Therapeutics, Inc. (DMRA) | Director | 1 | — | — | 1 |
| Oruka Therapeutics, Inc. (ORKA) | Director | 1 | — | — | 1 |
Insider filings — Turtle Cameron
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 600 @ $89.14 · Sale (S): 2,683 @ $90.10 · Sale (S): 2,638 @ $91.49 · Sale (S): 3,989 @ $92.31 · Sale (S): 4,990 @ $93.37 · Sale (S): 100 @ $93.91 | EDGAR |
| 2026-09-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 2,500 @ $86.36 · Sale (S): 8,400 @ $87.15 · Sale (S): 3,700 @ $88.06 · Sale (S): 400 @ $89.07 | EDGAR |
| 2026-08-05 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 800 @ $93.97 · Sale (S): 7,157 @ $95.10 · Sale (S): 5,635 @ $95.93 · Sale (S): 1,392 @ $96.82 · Sale (S): 16 @ $97.46 | EDGAR |
| 2026-07-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 10,176 @ $87.44 · Sale (S): 4,234 @ $88.12 · Sale (S): 590 @ $88.91 | EDGAR |
| 2026-06-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 3,557 @ $69.40 · Sale (S): 8,149 @ $70.50 · Sale (S): 3,294 @ $71.38 | EDGAR |
| 2026-05-01 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 5,300 @ $69.54 · Sale (S): 3,600 @ $70.77 · Sale (S): 1,000 @ $71.76 · Sale (S): 3,100 @ $73.14 · Sale (S): 1,700 @ $74.23 · Sale (S): 300 @ $74.96 | EDGAR |
| 2026-04-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 12,344 @ $49.20 · Sale (S): 2,656 @ $49.92 | EDGAR |
| 2026-03-25 | 4 | Damora Therapeutics, Inc. (DMRA) | Grant/award (A): 37,313 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 5,900 @ $41.73 · Sale (S): 9,100 @ $42.49 | EDGAR |
| 2026-02-04 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 957 @ $31.82 · Sale (S): 14,043 @ $32.87 | EDGAR |
| 2026-01-13 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 528,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 12,709 @ $30.47 · Sale (S): 2,191 @ $31.79 · Sale (S): 100 @ $32.39 | EDGAR |
| 2025-12-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 10,995 @ $28.73 · Sale (S): 4,005 @ $29.83 | EDGAR |
| 2025-11-05 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 28,155 @ $23.13 · Sale (S): 16,845 @ $23.66 | EDGAR |
| 2025-06-03 | 4 | Oruka Therapeutics, Inc. (ORKA) | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 400 @ $9.82 | EDGAR |
| 2024-02-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 277,750 (derivative) @ $0 | EDGAR |
| 2023-11-27 | 4 | Spyre Therapeutics, Inc. (AGLE) | Conversion (C): 723,440 @ $0 · Grant/award (A): 374,000 (derivative) @ $0 · Conversion (C): 18,086 (derivative) @ $0 | EDGAR |
| 2021-01-28 | 4 | Eidos Therapeutics, Inc. (EIDX) | Code (U): 50,699 · Disposition to issuer (D): 9,469 (derivative) · Disposition to issuer (D): 53,157 (derivative) | EDGAR |
| 2020-12-29 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 7,500 @ $17 · Option exercise (M): 6,000 @ $0.34 · Option exercise (M): 6,000 @ $0.16 · Sale (S): 10,937 @ $69.34 · Sale (S): 8,563 @ $69.94 · Option exercise (M): 7,500 (derivative) @ $0 · +2 more | EDGAR |
| 2020-12-16 | 4 | Eidos Therapeutics, Inc. (EIDX) | Option exercise (M): 4,451 @ $17 · Option exercise (M): 21,843 @ $13.20 · Sale (S): 3,756 @ $110.29 · Sale (S): 7,600 @ $111.31 · Sale (S): 11,445 @ $112.19 · Sale (S): 3,493 @ $112.97 · +2 more | EDGAR |
| 2020-11-25 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 4,258 @ $17 · Sale (S): 4,258 @ $47.00 · Option exercise (M): 742 @ $17 · Sale (S): 742 @ $47.23 · Option exercise (M): 4,258 (derivative) @ $0 · Option exercise (M): 742 (derivative) @ $0 | EDGAR |
| 2020-11-13 | 4 | Eidos Therapeutics, Inc. (EIDX) | Sale (S): 3,005 @ $73.56 · Sale (S): 9,497 @ $74.75 · Sale (S): 908 @ $75.23 · Gift (G): 1,500 @ $0 | EDGAR |
| 2020-11-09 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 2,500 @ $17 · Sale (S): 2,500 @ $42.05 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2020-11-03 | 4 | Eidos Therapeutics, Inc. (EIDX) | Option exercise (M): 5,000 @ $13.20 · Option exercise (M): 2,500 @ $17 · Sale (S): 9,145 @ $70.44 · Sale (S): 3,146 @ $71.42 · Sale (S): 209 @ $72.10 · Option exercise (M): 5,000 (derivative) @ $0 · +1 more | EDGAR |
| 2020-10-02 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 2,500 @ $17 · Option exercise (M): 6,000 @ $0.16 · Option exercise (M): 6,000 @ $0.34 · Sale (S): 12,442 @ $37.59 · Sale (S): 2,058 @ $38.24 · Option exercise (M): 2,500 (derivative) @ $0 · +2 more | EDGAR |
| 2020-09-22 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 2,500 @ $17 · Sale (S): 2,500 @ $42.01 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2020-09-16 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 2,500 @ $17 · Sale (S): 2,500 @ $37.06 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2020-09-15 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 2,000 @ $0.34 · Sale (S): 2,000 @ $35.02 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2020-09-11 | 4 | Eidos Therapeutics, Inc. (EIDX) | Option exercise (M): 2,500 @ $17 · Sale (S): 2,500 @ $47 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2020-09-02 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 2,745 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-26 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1758363 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs